Photopheresis in Early-stage Mycosis Fungoides

The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that patients with early stage CTCL may have markers in their blood which were previously observed primarily in late stage disease, such as clonal T cell populations. Considering these findings, the study aims to investigate whether photopheresis therapy may be used earlier in the disease course to produce a

Trial Details

NCT ID
NCT05680558
Phase
PHASE2
Sponsor
Columbia University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
  • THERAKOS® CELLEX photopheresis system
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Who are male or female, over the age of 18 and \<40 kg body weight with adequate veins to provide intravenous access.
  • Who are willing to adhere to the protocol and sign an Informed Patient Consent Document
  • Must not be on any other investigational device/drug treatment.
  • Who have the diagnosis of Mycosis Fungoides (MF) including a skin biopsy consistent with MF (atypical epidermotropic or folliculocentric T-cells) w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →